Literature DB >> 12630758

Treatment with sildenafil for the healing of refractory skin ulcerations in the antiphospholipid syndrome.

E Gertner1.   

Abstract

Nonhealing skin ulceration is a cutaneous manifestation of the antiphospholipid syndrome (APS) and is associated with thrombosis of small dermal vessels. Numerous therapies have been described but are either ineffective or require a prolonged course of treatment with potential complications. We describe the efficacy of sildenafil, a phosphodiesterase inhibitor, in the treatments of such ulcers.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12630758     DOI： 10.1191/0961203303lu257cr

Source DB:  PubMed          Journal:  Lupus        ISSN： 0961-2033            Impact factor:   2.911


  9 in total

Review 1.  Difficult clinical situations in the antiphospholipid syndrome.

Authors:  Renata Ferreira Rosa; Michelle Remião Ugolini-Lopes; Audrey Krüse Zeinad-Valim; Elbio D'Amico; Danieli Andrade
Journal:  Curr Rheumatol Rep       Date:  2015-04       Impact factor: 4.592

Review 2.  [Medicinal vasoactive therapy of microcirculation disorders in rheumatoid arthritis].

Authors:  G Riemekasten; H Schulze-Koops
Journal:  Z Rheumatol       Date:  2005-03       Impact factor: 1.372

3.  Tadalafil therapy and severe chronic foot wound resolution.

Authors:  Claire Davenport; Andrew Dubin
Journal:  Int Wound J       Date:  2015-02-03       Impact factor: 3.315

4.  Leg ulcers in antiphospholipid syndrome secondary to systemic lupus erythematosus treated with intravenous immunoglobulin.

Authors:  Guida Santos; Alexandre João; Lourdes Sousa
Journal:  J Dermatol Case Rep       Date:  2014-06-30

Review 5.  Phosphodiesterase type 5 and cancers: progress and challenges.

Authors:  Ines Barone; Cinzia Giordano; Daniela Bonofiglio; Sebastiano Andò; Stefania Catalano
Journal:  Oncotarget       Date:  2017-10-12

6.  Fast Cicatrization of Extensive Livedoid Vasculopathy Ulcers under Treatment with Sildenafil.

Authors:  Lediane Moreira Lopes; Guilherme Gomes Dias Campos; Matheus Augusto Eisenreich; Aline Defaveri do Prado; Markus Bredemeier
Journal:  Ann Dermatol       Date:  2017-02-03       Impact factor: 1.444

7.  Sildenafil, a Type-5 Phosphodiesterase Inhibitor, Fails to Reverse Myeloid-Derived Suppressor Cell-Mediated T Cell Suppression in Cells Isolated From Tuberculosis Patients.

Authors:  Vinzeigh N Leukes; Stephanus T Malherbe; Andriette Hiemstra; Leigh A Kotze; Kelly Roos; Alana Keyser; Dalene De Swardt; Andrea Gutschmidt; Gerhard Walzl; Nelita du Plessis
Journal:  Front Immunol       Date:  2022-07-22       Impact factor: 8.786

8.  Extensive abdominal wall ulceration as a late manifestation of antiphospholipid syndrome: a case report.

Authors:  Yogesh Sharma; Karen Humphreys; Campbell Thompson
Journal:  J Med Case Rep       Date:  2018-08-14

Review 9.  Myeloid-Derived Suppressor Cells as Target of Phosphodiesterase-5 Inhibitors in Host-Directed Therapeutics for Tuberculosis.

Authors:  Vinzeigh Leukes; Gerhard Walzl; Nelita du Plessis
Journal:  Front Immunol       Date:  2020-03-25       Impact factor: 7.561
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.